Table 1 Baseline characteristics of included trials

Finerenone vs. placebo

FIDELIO-DKD

Finerenone

10/20

5674

2833

2841

65.4 ± 8.9

65.7 ± 9.2

1953 (68.9)

2030 (71.5)

31.1 ± 6.0

31.1 ± 6.0

FIGARO-DKD

Finerenone

10/20

7352

3686

3666

64.1 ± 9.7

64.1 ± 10.0

2528 (68.6)

2577 (70.3)

31.5 ± 6.0

31.4 ± 5.9

ARTS-DN

Finerenone

1.25/2.5/5/7.5/10/15/20

823

729

94

64.33 ± 9.20

63.26 ± 8.68

570 (78.4)

69 (73.4)

31.75 ± 5.57

32.49 ± 5.27

GLP-1RA vs. placebo

ELIXA

Lixisenatide

0.01

6068

3034

3034

59.9 ± 9.7

60.6 ± 9.6

2111 (69.6)

2096 (69.1)

30.1 ± 5.6

30.2 ± 5.8

LEADER

Liraglutide

1.8

9340

4668

4672

64.2 ± 7.2

64.4 ± 7.2

3011 (64.5)

2992 (64.0)

32.5 ± 6.3

32.5 ± 6.3

SUSTAIN-6

Semaglutide

0.5/1 weekly

3297

1648

1649

64.7 ± 7.2

64.6 ± 7.5

1013 (61.5)

989 (60.0)

32.8 ± 6.2

32.8 ± 6.2

EXSCEL

Exenatide

2 weekly

14,752

7356

7396

61.8 ± 9.4

61.9 ± 9.4

4562 (62.0)

4587 (62.0)

32.7 ± 6.4

HARMONY

Albiglutide

30/50

9463

4731

4732

64.1 ± 8.7

64.2 ± 8.7

3304 (70.0)

3265 (69.0)

32.3 ± 5.9

32.3 ± 5.9

REWIND

Dulaglutide

1.5 weekly

9901

4949

4952

66.2 ± 6.5

66.2 ± 6.5

2643 (53.4)

2669 (53.9)

32.3 ± 5.7

32.3 ± 5.8

AMPLITUDE-O

Exenatide

2 weekly

4076

2717

1359

64.6 ± 8.2

64.4 ± 8.3

1792 (66.0)

940 (69.2)

32.9 ± 6.2

32.4 ± 6.0

PIONEER 6

Semaglutide

14

3183

1591

1592

66 ± 7

66 ± 7

1084 (68.1)

1092 (68.6)

32.3 ± 6.6

32.3 ± 6.4